These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29188425)

  • 21. Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.
    Escolar G; Díaz-Ricart M; Arellano-Rodrigo E
    Drugs Today (Barc); 2017 Aug; 53(8):423-434. PubMed ID: 29119147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis.
    Laskier V; Guy H; Fisher M; Neuman WR; Bucior I; Cohen AT; Ren S
    J Med Econ; 2019 Oct; 22(10):1063-1072. PubMed ID: 31314619
    [No Abstract]   [Full Text] [Related]  

  • 23. Betrixaban for prevention of venous thromboembolism in acute medically ill patients.
    Beyer-Westendorf J; Verhamme P; Bauersachs R
    Eur Heart J Suppl; 2018 May; 20(Suppl E):E16-E22. PubMed ID: 29977165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Betrixaban: A Novel Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients.
    Lee K; Cham S; Lam S
    Cardiol Rev; 2018; 26(6):331-338. PubMed ID: 30067518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Chi G; Goldhaber SZ; Kittelson JM; Turpie AGG; Hernandez AF; Hull RD; Gold A; Curnutte JT; Cohen AT; Harrington RA; Gibson CM
    J Thromb Haemost; 2017 Oct; 15(10):1913-1922. PubMed ID: 28762617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative.
    Barkoudah E; Piazza G; Hecht TEH; Grant P; Deitelzweig S; Fang MC; Fanikos J; Kao CK; Barnes GD; Chen T; Ramishvili T; Schnipper JL; Goldstein JN; Ruff CT; Kaatz S; Schwartz A; Connors JM; Goldhaber SZ
    Am J Med; 2020 May; 133 Suppl 1():1-27. PubMed ID: 32362349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy.
    Chi G; Gibson CM; Hernandez AF; Hull RD; Kazmi SHA; Younes A; Walia SS; Pitliya A; Singh A; Kahe F; Kalayci A; Nafee T; Kerneis M; AlKhalfan F; Cohen AT; Harrington RA; Goldhaber SZ
    Am J Med; 2018 Aug; 131(8):972.e1-972.e7. PubMed ID: 29660351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).
    Chi G; Yee MK; Amin AN; Goldhaber SZ; Hernandez AF; Hull RD; Cohen AT; Harrington RA; Gibson CM
    Circulation; 2018 Jan; 137(1):91-94. PubMed ID: 29279341
    [No Abstract]   [Full Text] [Related]  

  • 29. Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial.
    Gibson CM; Jennings LK; Chi G; Yee MK; Halaby R; Nafee T; AlKhalfan F; Kerneis M; Korjian S; Daaboul Y; Goldhaber SZ; Hull RD; Hernandez AF; Cohen AT; Harrington RA
    TH Open; 2018 Jan; 2(1):e16-e24. PubMed ID: 31249924
    [No Abstract]   [Full Text] [Related]  

  • 30. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients.
    Cave B; Hough A; Dobesh PP
    Pharmacotherapy; 2018 Jun; 38(6):597-609. PubMed ID: 29543384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials.
    Liew AY; Piran S; Eikelboom JW; Douketis JD
    J Thromb Thrombolysis; 2017 Apr; 43(3):291-301. PubMed ID: 27900627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
    Turpie AG; Bauer KA; Davidson BL; Fisher WD; Gent M; Huo MH; Sinha U; Gretler DD;
    Thromb Haemost; 2009 Jan; 101(1):68-76. PubMed ID: 19132191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial.
    Chi G; Goldhaber SZ; Hull RD; Hernandez AF; Kerneis M; Al Khalfan F; Cohen AT; Harrington RA; Gibson CM
    Thromb Haemost; 2017 Dec; 117(12):2389-2395. PubMed ID: 29212126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended Thromboprophylaxis With Betrixaban or Rivaroxaban for Acutely Ill Hospitalized Medical Patients: Meta-Analysis of Prespecified Subgroups.
    Jamil A; Jamil U; Singh K; Khan F; Chi G
    Crit Pathw Cardiol; 2021 Mar; 20(1):16-24. PubMed ID: 32657973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The benefit of betrixaban for the extended thromboprophylaxis in acutely ill medical patients.
    Scarpa D; Denas G; Babuin L; Pengo V
    Expert Opin Pharmacother; 2019 Feb; 20(3):261-268. PubMed ID: 30615495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial.
    Chi G; Violi F; Pignatelli P; Vestri A; Spagnoli A; Loffredo L; Hernandez AF; Hull RD; Cohen AT; Harrington RA; Goldhaber SZ; Gibson CM
    J Thromb Thrombolysis; 2023 Feb; 55(2):211-221. PubMed ID: 36566304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct oral anticoagulants for extended-duration thromboprophylaxis in hospitalized medically ill patients: are we there yet?
    Al Yami MS; Alfayez OM; Kurdi SM; Alsheikh R
    J Thromb Thrombolysis; 2017 Jul; 44(1):1-8. PubMed ID: 28197755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
    Hull RD; Schellong SM; Tapson VF; Monreal M; Samama MM; Nicol P; Vicaut E; Turpie AG; Yusen RD;
    Ann Intern Med; 2010 Jul; 153(1):8-18. PubMed ID: 20621900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Betrixaban in the prevention of venous thromboembolism in medically ill patients.
    Sylvester KW; Connors JM
    Future Cardiol; 2018 Nov; 14(6):455-470. PubMed ID: 30353749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial.
    Kalayci A; Gibson CM; Hernandez AF; Hull RD; Cohen AT; Fitzgerald C; Hussain SD; Chi G; Alkhalfan F; Harrington RA; Goldhaber SZ
    Thromb Res; 2022 Mar; 211():63-69. PubMed ID: 35091313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.